Factors Associated with Unsuccessful Treatment of Bedaquiline and or Delamanid Based Regimens in Multidrug-Resistant Tuberculosis: A Review
-
Published:2023-06-12
Issue:
Volume:
Page:923-934
-
ISSN:2656-3088
-
Container-title:Journal of Pharmaceutical and Sciences
-
language:
-
Short-container-title:JPS
Author:
Nugraha Putra Oki,Faizah Ana Khusnul,Wijayanti D.N Nani
Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) is a serious health concern that is difficult to treat, requiring long and complex treatment with highly effective drugs. An all-oral regimen, bedaquiline and or delamanid have already shown low unsuccessful treatment in patients with MDR-TB. Method: We comprehensively reviewed factors associated with unsuccessful treatment (death, treatment failure, and loss to follow-up) related to all oral regimen containing bedaquiline and or delamanid in patients with MDR-TB. We conducted a scoping review under the PRISMA guideline for scoping review. Results: We included seven observational studies that met the inclusion criteria. Four studies reported the concomitant use of bedaquiline and delamanid. Unsuccessful treatment ranged from 7.8% to 36.6% in regimens containing bedaquiline, delamanid, or both at six months or after treatment completion. Low rates of treatment failure and loss to follow-up were reported in the included studies. Elderly, being underweight (BMI < 18.5 kg/m2), and hepatitis C coinfection among MDR-TB patients were associated with unsuccessful treatment in most studies. None studies reported pre-XDR and XDR-TB as risk factors for unsuccessful treatment. Conclusion: In MDR-TB patients receiving regimens containing bedaquiline and delamanid, age, BMI, and hepatitis C coinfection were associated with unsuccessful treatment.
Publisher
Universitas Tjut Nyak Dhien
Reference45 articles.
1. Auchynka, V., Kumar, A. M. V., Hurevich, H., Sereda, Y., Solodovnikova, V., Katovich, D., et al. 2021). Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrugresistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18. In Monaldi Archives for Chest Disease;91(1). https://doi.org/10.4081/MONALDI.2021.1647 2. Behzadifar, M., Heydarvand, S., Behzadifar, M., & Bragazzi, N. L. (2019). Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis. Ethiopian Journal of Health Sciences, 29(1), 945–956. https://doi.org/10.4314/ejhs.v29i1.17 3. Bonavida, V., Frame, M., Nguyen, K. H., Rajurkar, S., & Venketaraman, V. (2022). Mycobacterium tuberculosis: Implications of Ageing on Infection and Maintaining Protection in the Elderly. Vaccines, 10(11), 1892. https://doi.org/10.3390/vaccines10111892 4. Chen, X., Hashizume, H., Tomishige, T., Nakamura, I., Matsuba, M., Fujiwara, M., Kitamoto, R., Hanaki, E., Ohba, Y., & Matsumoto, M. (2017). Delamanid kills dormant mycobacteria in vitro and in a Guinea pig model of tuberculosis. Antimicrobial Agents and Chemotherapy, 61(6), 1–11. https://doi.org/10.1128/AAC.02402-16 5. Gao, M., Gao, J., Xie, L., Wu, G., Chen, W., Chen, Y., et al. (2021). Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clinical Microbiology and Infection, 27(4), 597–602. https://doi.org/10.1016/j.cmi.2020.06.004
|
|